Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Buprenorphine (BPN) has been shown to rapidly improve mood in treatment-resistant depressed patients in small clinical studies. However, BPN’s effects in preclinical tests for mood and antidepressant efficacy are largely unexplored. The current study examined the effects of BPN in the forced swim test (FST) and novelty-induced hypophagia (NIH) test as measures of antidepressant and anxiolytic-like effects in C57BL/6 J mice. Microdialysis was used to measure whether BPN engaged kappa-opioid receptor (KORs) in the nucleus accumbens shell (NAcSh) at a behaviorally active dose (0.25 mg/kg). BPN was tested in the FST at both 30 min and 24 h post-administration. Also measured in the FST at 24 h post-administration were the KOR antagonist norbinaltorphimine (nor-BNI), the MOR agonist morphine and the reference antidepressant desipramine. The anxiolytic effects of BPN were examined in the NIH test 24 h after treatment. The effects of acute injection of BPN and the KOR agonist U50,488 were measured on extracellular dopamine (DA) levels in the NAcSh. BPN produced significant reductions in FST immobility without changing locomotor activity and reduced approach latencies in the novel environment of the NIH test when tested 24 h after treatment. Repeated daily BPN injections for 6 days did not produce tolerance to these behavioral effects. nor-BNI produced a similar antidepressant-like response in the FST 24 h post-injection but morphine and desipramine were ineffective. BPN (0.25 mg/kg) did not alter DA levels when given alone but prevented the KOR agonist U50,488 from reducing DA levels. Acute and subchronic treatment with BPN produced antidepressant and anxiolytic-like responses in mice at doses that engage KORs. These studies support the clinical evidence that BPN may be a novel rapid-acting antidepressant medication and provides rodent models for investigating associated neurochemical mechanisms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“This pattern of sustained behavioral effects is also seen with ketamine (Autry et al. 2011), a novel fastacting antidepressant (Murrough et al. 2013), and could be an emerging hallmark for rapid-acting antidepressants in animal studies.”
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Di Chiara, G., & Imperato, A. (1988) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24578-5 · Cited by 916
Treatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796 · cited 1×
“In fact, approximately 30 % of patients suffer from treatment-resistant depression (TRD), where they do not respond to at least two antidepressant medications (Al-Harbi 2012).”
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., aan het Rot, M., Collins, K. A., Mathew, S. J., Charney, D. S., & Iosifescu, D. V. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.022 · Cited by 786 · cited 2×
“2011), a novel fastacting antidepressant (Murrough et al. 2013), and could be an emerging hallmark for rapid-acting antidepressants in animal studies.”
Effects of Chronic Fluoxetine in Animal Models of Anxiety and Depression
Dulawa, S. C., Holick, K. A., Gundersen, B., & Hen, R. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300433 · Cited by 671 · cited 1×
“The NIH test is an anxiety-like behavior test in rodents that is sensitive to the anxiolytic effects of antidepressants emerging following chronic treatment for weeks, but not following subchronic or acute treatments (Dulawa et al. 2004; Dulawa and Hen 2005; Bechtolt et al. 2008; Balu et al. 2009).”
Opioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542
Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in Rats
Mague, S. D., Pliakas, A. M., Todtenkopf, M. S., Tomasiewicz, H. C., Zhang, Y., Stevens, W. C., Jones, R. M., Portoghese, P. S., & Carlezon, W. A. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.046433 · Cited by 485 · cited 1×
“Furthermore, several animal studies have shown that KOR antagonists produce anxiolytic and antidepressant-like responses (Mague et al. 2003; Knoll et al. 2007, 2011; Carr et al. 2010; Carr and Lucki 2010).”
The Impact of Treatment-Resistant Depression on Health Care Utilization and Costs
Crown, W. H., Finkelstein, S., Berndt, E. R., Ling, D., Poret, A. W., Rush, A. J., & Russell, J. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1102 · Cited by 386
Do animal models of anxiety predict anxiolytic-like effects of antidepressants?
Borsini, F., Podhorna, J., & Marazziti, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1155-6 · Cited by 347 · cited 4×
“2007, 2011), although this behavioral test does not predict the anxiolytic effects of chronic antidepressant treatment (Borsini et al. 2002).”
Influential
Cited by
Antidepressant-like Effects of Buprenorphine are Mediated by Kappa Opioid Receptors
Falcon, E., Browne, C. A., Leon, R. M., Fleites, V. C., Sweeney, R., Kirby, L. G., & Lucki, I. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.38 · Cited by 118
“BPN hydrochloride (Sigma, St Louis, MO and NIDA), norBNI (Tocris Bioscience, Ellisville, MO) and desipramine hydrochloride (DMI; Sigma) were administered at doses previously found to have antidepressant activity in the FST (Falcon et al, 2015; Lucki et al, 2001; McLaughlin et al, 2003).”
MethodInfluentialSelf-citationEpigenetic Regulation of the Kappa Opioid Receptor by Child Abuse
Lutz, P.-E., Gross, J. A., Dhir, S. K., Maussion, G., Yang, J., Bramoulle, A., Meaney, M. J., & Turecki, G. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.07.012 · Cited by 96
The opioid system and the social brain: implications for depression and suicide
Lutz, P., Courtet, P., & Calati, R. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24269 · Cited by 53
Ahmadi, J., Jahromi, M. S., & Ehsaei, Z. (2018) · Trials · doi:10.1186/s13063-018-2843-9 · Cited by 48
The Role of Opiates in Social Pain and Suicidal Behavior
Nobile, B., Lutz, P.-E., Olie, E., & Courtet, P. (2020) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_167 · Cited by 24
Metadata
- Authors
- Falcon, E., Maier, K., Robinson, S. A., Hill-Smith, T. E., & Lucki, I.
- Venue
- Psychopharmacology
- Published
- 2014-09-03
- Volume
- 232
- Issue
- 5
- Pages
- 907-915
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1972357973
- Cited by
- 84
- References
- 17
- FWCI
- 5.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. https://app.cochat.ai/papers/10.1007/s00213-014-3723-y
- The paper
- Falcon, E., Maier, K., Robinson, S. A., Hill-Smith, T. E., & Lucki, I. (2015). Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice. Psychopharmacology. https://doi.org/10.1007/s00213-014-3723-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.